1. Home
  2. MNTK vs MLYS Comparison

MNTK vs MLYS Comparison

Compare MNTK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Montauk Renewables Inc.

MNTK

Montauk Renewables Inc.

HOLD

Current Price

$2.27

Market Cap

267.6M

Sector

Utilities

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.93

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTK
MLYS
Founded
1980
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.6M
2.5B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
MNTK
MLYS
Price
$2.27
$27.93
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$1.80
$48.67
AVG Volume (30 Days)
310.5K
1.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
$176,382,000.00
N/A
Revenue This Year
$18.55
N/A
Revenue Next Year
$12.68
N/A
P/E Ratio
$146.00
N/A
Revenue Growth
0.37
N/A
52 Week Low
$1.07
$22.30
52 Week High
$2.73
$47.65

Technical Indicators

Market Signals
Indicator
MNTK
MLYS
Relative Strength Index (RSI) 57.32 50.33
Support Level $1.49 $25.56
Resistance Level $2.73 $28.14
Average True Range (ATR) 0.20 1.68
MACD -0.01 -0.06
Stochastic Oscillator 54.19 39.69

Price Performance

Historical Comparison
MNTK
MLYS

About MNTK Montauk Renewables Inc.

Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: